Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141538

Published: 2020

Journal Articles

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Francesco Mazziotta, MD, Gabriele Buda, MD PhD, Nadia Cecconi, MD, Giulia Cervetti, MD, Lorenzo Iovino, MD, Enrico Orciuolo, MD PhD, Matteo Pelosini, MD PhD, Edoardo Benedetti, MD, Francesco Caracciolo, MD, Giovanni Carulli, MD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD

Blood (2019) 134 (Supplement_1): 3254.

https://doi.org/10.1182/blood-2019-126118

Published: 2019

Journal Articles

Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant

Lorenzo Iovino, MD, Sinéad Kinsella, MSc,PhD, Kirsten Cooper, Reema Jain, PhD, Paul DeRoos, Alex Gagnon, Tamas M Ugrai, Gabriele Buda, MD PhD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD, Jarrod A Dudakov, PhD

Blood (2019) 134 (Supplement_1): 4422.

https://doi.org/10.1182/blood-2019-129290

Published: 2019

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Coagulopathy in Patients with Plasmacellular Dyscrasia

Francesca Martini, Gabriele Buda, MD PhD, Nadia Cecconi, Dr, Laura Caponi, Aldo Paolicchi, MD, Mario Petrini, PhD MD Prof

Blood (2017) 130 (Supplement 1): 4867.

https://doi.org/10.1182/blood.V130.Suppl_1.4867.4867

Published: 2017

Journal Articles

Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaϊVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study

Lorenzo Iovino, MD, Enrico Orciuolo, MD PhD, Gabriele Buda, MD PhD, Giovanni Carulli, MD, Fabrizio Maggi, Dr, Daniele Focosi, MD, Riccardo Morganti, Dr, Francesca Guerrini, PhD, Sara Galimberti, MD PhD, Mario Petrini, MD PhD

Blood (2016) 128 (22): 1230.

https://doi.org/10.1182/blood.V128.22.1230.1230

Published: 2016

Journal Articles

Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Gabriele Buda, MD PhD, Rita Fazzi, Giovanni Carulli, MD, Sara Galimberti, MD PhD, Paola Sammuri, Enrico Orciuolo, MD PhD, Iacopo Petrini, Fabrizio Accardi, MD, Laura Notarfranchi, MD, Nicola Giuliani, Mario Petrini

Blood (2016) 128 (22): 5697.

https://doi.org/10.1182/blood.V128.22.5697.5697

Published: 2016

NARROW

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Coagulopathy in Patients with Plasmacellular Dyscrasia

Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaϊVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study

Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma

Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Coagulopathy in Patients with Plasmacellular Dyscrasia

Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ NaϊVe and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study

Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only